An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON).

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509004-15-00

Acronym

D6185C00001

Enrollment

172

Registered

2024-08-09

Start date

2018-02-20

Completion date

Unknown

Last updated

2025-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with non-small cell lung cancer (NSCLC).

Brief summary

Endpoint based on Response Evaluation Criteria in Solid Tumours (RECIST 1.1) Objective response rate (ORR)

Detailed description

Overall Survival (OS)., Endpoints based on RECIST 1.1 including: Disease control rate (DCR), Endpoints based on RECIST 1.1 including: Best percentage change in tumour size, Endpoints based on RECIST 1.1 including: Duration of response (DoR), Endpoints based on RECIST 1.1 including: Progression free survival (PFS).

Interventions

DRUGINFLIXIMAB

DRUGDS-8201a

DRUGAZD6738

DRUGMYCOPHENOLATE MOFETIL

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Endpoint based on Response Evaluation Criteria in Solid Tumours (RECIST 1.1) Objective response rate (ORR)	—

Secondary

Measure	Time frame
Overall Survival (OS)., Endpoints based on RECIST 1.1 including: Disease control rate (DCR), Endpoints based on RECIST 1.1 including: Best percentage change in tumour size, Endpoints based on RECIST 1.1 including: Duration of response (DoR), Endpoints based on RECIST 1.1 including: Progression free survival (PFS).	—

Countries

Austria, France, Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026